Monday, AbbVie Inc. (ABBV) announced that SKYRIZI has been listed for the treatment of moderately to severely active ulcerative colitis on the public drug formularies in Ontario and Alberta.
Additionally, Canada's Drug Agency has recommended SKYRIZI to be reimbursed with conditions by public drug plans.
"This is a testament to AbbVie's and the Health Institutions' continuous progress in expanding patient access to innovative medicines for inflammatory bowel disease" said Arima Ventin, Director, Market Access and Government Affairs, AbbVie Canada.
In the pre-market hours, ABBV is trading at $206.10, down 0.23 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.